These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23970015)

  • 1. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
    Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
    Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
    Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
    Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
    Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
    Alba E; Lluch A; Ribelles N; Anton-Torres A; Sanchez-Rovira P; Albanell J; Calvo L; García-Asenjo JA; Palacios J; Chacon JI; Ruiz A; De la Haba-Rodriguez J; Segui-Palmer MA; Cirauqui B; Margeli M; Plazaola A; Barnadas A; Casas M; Caballero R; Carrasco E; Rojo F
    Oncologist; 2016 Feb; 21(2):150-5. PubMed ID: 26786263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
    Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL
    BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
    von Minckwitz G; Müller BM; Loibl S; Budczies J; Hanusch C; Darb-Esfahani S; Hilfrich J; Weiss E; Huober J; Blohmer JU; du Bois A; Zahm DM; Khandan F; Hoffmann G; Gerber B; Eidtmann H; Fend F; Dietel M; Mehta K; Denkert C
    J Clin Oncol; 2011 Jun; 29(16):2150-7. PubMed ID: 21519019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study.
    Klauschen F; Wienert S; Schmitt WD; Loibl S; Gerber B; Blohmer JU; Huober J; Rüdiger T; Erbstößer E; Mehta K; Lederer B; Dietel M; Denkert C; von Minckwitz G
    Clin Cancer Res; 2015 Aug; 21(16):3651-7. PubMed ID: 25501130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.